Showing results (171-180 of 221) with videos related to
Sort By:
Pageof 23
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 29, 2023
Clinicopathologic Features of Therapy-Related Myeloid Neoplasms in Patients with Myeloma in the Era of Novel TherapiesFatima Zahra Jelloul, Andres E Quesada, Richard K Yang, et al.Blood Advances|April 7, 2020
Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimensCurtis A Lachowiez, Sanam Loghavi, Tapan M Kadia, et al.Journal of Cutaneous Pathology|September 9, 2017
Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemiaSanam Loghavi, Jonathan L Curry, Guillermo Garcia-Manero, et al.Journal of the National Cancer Institute|April 12, 2015
A decision support framework for genomically informed investigational cancer therapyFunda Meric-Bernstam, Amber Johnson, Vijaykumar Holla, et al.The Journal of Molecular Diagnostics : JMD|July 30, 2026
Analytical Validation of a Plasma-Based Rapid Liquid Biopsy Assay Using Next-Generation SequencingSinchita Roy-Chowdhuri, Ana Galan-Cobo, Nitin Agarwal, et al.American Journal of Hematology|September 2, 2022
Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remissionNicholas J Short, Walid Macaron, Tapan Kadia, et al.British Journal of Haematology|June 28, 2019
Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patientsBoyu Hu, Keyur P Patel, Hsiang-Chun Chen, et al.Blood|January 24, 2018
Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomideKoichi Takahashi, Boyu Hu, Feng Wang, et al.Cancer|October 29, 2020
Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutationsMahran Shoukier, Tapan Kadia, Marina Konopleva, et al.Leukemia & Lymphoma|October 20, 2021
Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapyJorge M Ramos Perez, Keyur P Patel, Sanam Loghavi, et al.Pageof 23